Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 5/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636511 | 0.80 | HPGDS (1.00) | HPGDSL3MBTL1EPHX2HDAC6HDAC2 | |
| SCHEMBL429327 | 0.79 | SMN1; SMN2 (0.61) | HPGDSL3MBTL1EPHX2HDAC6HDAC2 | |
| SCHEMBL11979758 | 0.78 | MAPK14 (0.76) | EPHX2HDAC6HDAC2HDAC8HDAC1 | |
| SCHEMBL15646383 | 0.78 | NAMPT (0.63) | HDAC6HDAC2HDAC1HDAC3LMNA | |
| SCHEMBL5019736 | 0.77 | NAMPT (0.73) | LMNARAB9A | |
| SCHEMBL14005262 | 0.77 | HPGDS (0.67) | HPGDSL3MBTL1HDAC6HDAC2HDAC8 | |
| SCHEMBL5077115 | 0.76 | HPGDS (0.67) | HPGDSL3MBTL1HDAC6HDAC2HDAC8 | |
| SCHEMBL13210567 | 0.76 | L3MBTL1 (0.76) | HPGDSL3MBTL1EPHX2HDAC6HDAC2 | |
| SCHEMBL10077690 | 0.76 | L3MBTL1 (0.71) | HPGDSL3MBTL1EPHX2HDAC6HDAC2 | |
| SCHEMBL2634030 | 0.75 | MAPK14 (0.76) | EPHX2HDAC6HDAC2HDAC8HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132505-A1 | Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine | CNR2, CNR1, PDE4A | HPGDS 387/4885L3MBTL1 4731/4885EPHX2 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.